×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BMY – bristol-myers squibb company (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BMY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/26
04:14 pm
bmy
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
Low
Report
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
2/26
11:23 am
bmy
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy? [Yahoo! Finance]
Low
Report
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy? [Yahoo! Finance]
2/26
07:24 am
bmy
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer [Yahoo! Finance]
Low
Report
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer [Yahoo! Finance]
2/26
06:59 am
bmy
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Low
Report
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
2/26
06:27 am
bmy
Bristol Myers Squibb (BMY) was upgraded by Royal Bank Of Canada to "hold".
Low
Report
Bristol Myers Squibb (BMY) was upgraded by Royal Bank Of Canada to "hold".
2/25
10:28 pm
bmy
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow [Yahoo! Finance]
Low
Report
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow [Yahoo! Finance]
2/25
10:12 am
bmy
Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie [Yahoo! Finance]
Low
Report
Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie [Yahoo! Finance]
2/24
06:04 pm
bmy
Bristol Myers Squibb (BMY) is now covered by Royal Bank Of Canada. They set a "sector perform" rating on the stock.
Low
Report
Bristol Myers Squibb (BMY) is now covered by Royal Bank Of Canada. They set a "sector perform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
2/6/2026
04:05 pm
bmy
bristol-myers squibb company
BEAT
Report
-1.9%
bristol-myers squibb company
2/5/2026
04:03 pm
bmy
bristol-myers squibb company
BEAT
Report
4.9%
bristol-myers squibb company
2/5/2026
07:33 am
bmy
bristol-myers squibb company
BEAT
Report
1.7%
bristol-myers squibb company
10/31/2025
04:03 pm
bmy
bristol-myers squibb company
BEAT
Report
-0.1%
bristol-myers squibb company
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/11
11:35 am
bmy
Form 10-K BRISTOL MYERS SQUIBB CO For: Dec 31
Low
Report
Form 10-K BRISTOL MYERS SQUIBB CO For: Dec 31
2/5
07:08 am
bmy
Form 8-K BRISTOL MYERS SQUIBB CO For: Feb 05
Low
Report
Form 8-K BRISTOL MYERS SQUIBB CO For: Feb 05
2/3
04:40 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Feb 01 Filed by: Meyers Gregory Scott
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Feb 01 Filed by: Meyers Gregory Scott
2/3
04:39 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Feb 01 Filed by: Hickey Benjamin
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Feb 01 Filed by: Hickey Benjamin
2/3
04:37 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Feb 01 Filed by: YALE PHYLLIS R
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Feb 01 Filed by: YALE PHYLLIS R
2/3
04:35 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Feb 01 Filed by: Vousden Karen H
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Feb 01 Filed by: Vousden Karen H
2/3
04:34 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Feb 01 Filed by: Samuels Theodore R. II
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Feb 01 Filed by: Samuels Theodore R. II
2/3
04:31 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Feb 01 Filed by: Rice Derica W
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Feb 01 Filed by: Rice Derica W
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/24
Bristol-Myers releases mixed Opdivo lung cancer results [Reuters]
10.2%
3/12 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: LEUNG SANDRA 7.9%
3/25 Form DEF 14A BRISTOL MYERS SQUIBB CO For: May 05 5.9%
4/8 Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer 4.3%
3/3 Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology 3.9%
4/3 Form 3 BRISTOL MYERS SQUIBB CO For: Mar 30 Filed by: Mily Elizabeth 3.4%
8/25 Better Buy: Biogen vs. Celgene [The Motley Fool] 3.1%
3/31 Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA 2.8%
4/20 Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma 2.8%
8/15 What Has Led Bristol-Myers Squibb's Stock To Fall More Than 35% Over The Last 3 Years? [Forbes] 2.7%
3/12 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: LEUNG SANDRA 7.9%
3/25 Form DEF 14A BRISTOL MYERS SQUIBB CO For: May 05 5.9%
4/8 Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer 4.3%
3/3 Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology 3.9%
4/3 Form 3 BRISTOL MYERS SQUIBB CO For: Mar 30 Filed by: Mily Elizabeth 3.4%
8/25 Better Buy: Biogen vs. Celgene [The Motley Fool] 3.1%
3/31 Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA 2.8%
4/20 Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma 2.8%
8/15 What Has Led Bristol-Myers Squibb's Stock To Fall More Than 35% Over The Last 3 Years? [Forbes] 2.7%
TOP News Decliners
6/24
Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
-7.8%
3/11 Nationwide class actions are safe, thanks to the D.C. and 7th Circuits [Reuters] -7.1%
10/22 Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise [Yahoo! Finance News] -4.9%
3/6 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 04 Filed by: Elicker John E -4.4%
3/20 Bristol-Myers Squibb, Sanofi strike out in bid to stop Plavix litigation [Seeking Alpha] -4.3%
3/18 Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development -4.3%
2/26 Form 4 BRISTOL MYERS SQUIBB CO For: Feb 03 Filed by: Metcalfe Kathryn -4.0%
3/16 BMY Stock Dives As Investors Worry Coronavirus Could Delay A Key Drug [Investor's Business Daily] -3.6%
4/7 Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S. -3.6%
4/20 Bristol Myers Squibb's Cancer Drug Opdivo Successful in 2 Clinical Trials [The Motley Fool] -3.5%
3/11 Nationwide class actions are safe, thanks to the D.C. and 7th Circuits [Reuters] -7.1%
10/22 Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise [Yahoo! Finance News] -4.9%
3/6 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 04 Filed by: Elicker John E -4.4%
3/20 Bristol-Myers Squibb, Sanofi strike out in bid to stop Plavix litigation [Seeking Alpha] -4.3%
3/18 Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development -4.3%
2/26 Form 4 BRISTOL MYERS SQUIBB CO For: Feb 03 Filed by: Metcalfe Kathryn -4.0%
3/16 BMY Stock Dives As Investors Worry Coronavirus Could Delay A Key Drug [Investor's Business Daily] -3.6%
4/7 Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S. -3.6%
4/20 Bristol Myers Squibb's Cancer Drug Opdivo Successful in 2 Clinical Trials [The Motley Fool] -3.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: